An article published by China Global Television Network (CGTN) claiming that the World Health Organization (WHO) has halted trials of hydroxychloroquine and HIV drugs as a potential treatment for COVID-19 is TRUE.
The trial used a combination of the malaria drug hydroxychloroquine and the HIV drug lopinavir/ritonavir for treatment, but failed to reduce mortality.
In a statement dated July 4, the global health body announced that trials were stopped following recommendations made by the steering committee of Solidarity Trials International.
Solidarity is an international clinical trial launched by the WHO and its partners to help find an effective treatment for COVID-19.
The recommendation was based on evidence presented during a WHO summit on COVID-19 research and innovation held from 1 to 2 July, which showed that the drugs used in the trial provided little or no mortality prevention in hospitalized COVID-19 patients compared to standard hospital care.
The WHO says that the decision to discontinue the trial in hospitalized patients does not affect the possible evaluation of the two drugs in non-hospitalized patients or in other studies. The interim Solidarity results are now being readied for peer-review publication.
Other drugs being investigated as potential COVID-19 treatments under the Solidarity trial program include the Ebola drug Remdesivir, and Interferon Beta-1a, which is used to treat multiple sclerosis.
PesaCheck has looked into the claim that the World Health Organization has halted trials of hydroxychloroquine and HIV drugs as a potential treatment for COVID-19, and finds it to be TRUE.
This story was produced by PesaCheck.